In 2017, the World Health Organization (WHO) established a new entity for MYC rearranged DLBCL, called ‘high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements’ [1, 4]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.